Medication persistence with weekly versus daily doses of orally administered bisphosphonates

摘要: ABSTRACT Objective To compare medication persistence among patients receiving daily orally administered bisphosphonates with weekly to ascertain whether less frequent dosing is associated better long-term treatment persistence. Methods A large, longitudinal cohort of female (N = 211,319) prescriptions for alendronate or risedronate from approximately 14,000 US retail pharmacies was assessed. Medication defined as the percentage who continued take bisphosphonate therapy during each month (that is, having at least 1 day supply in that month) a 1-year observation period. Results The inconvenience and complexity required procedures oral prevention osteoporosis are thought be major factors hinder persistence, poor suboptimal health-care outcomes. In this study, continuing steadily declined both regimens course 12-month Consistently, however, higher rather than regimen. Only 56.7% regimen only 39.0% 12 study period (P  Conclusion This demonstrates dosing. Nevertheless, more 40% did not persist months. Thus, inadequate even use Additional research needed determine can further improved by extending interval beyond once weekly. (Endocr Pract. 2006;12:522-528)